Cath Lab

The catheterization lab channel includes content related to interventional technologies for coronary and peripheral artery disease (PAD). Other cath lab transcatheter device technologies covered on this page included percutaneous treatment for stroke, venous interventions, heart valves, hypertensionheart failure and percutenous coronary interventions (PCI).

DSA image obtained approximately 24 hours after 1 mg/h IA tPA infusion, 500 U/h heparin via peripheral IV, and daily oral aspirin (81 mg) shows improved perfusion of digital arteries, albeit with suboptimal vascular blush of distal second and third phalanges. Photo courtesy of ARRS

DSA image obtained approximately 24 hours after 1 mg/h IA tPA infusion, 500 U/h heparin via peripheral IV, and daily oral aspirin (81 mg) shows improved perfusion of digital arteries, albeit with suboptimal vascular blush of distal second and third phalanges. Photo courtesy of ARRS

News | Interventional Radiology | February 11, 2020

February 11, 2020 — An ahead-of-print...

The Aria CV Pulmonary Hypertension System (Aria CV PH System) received FDA Breakthrough Device status.
News | Hypertension | February 07, 2020

February 7, 2020 — The U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation for the...

The American College of Cardiology (ACC) released a list of the latest practice-changing presentations at the ACC.20 annual meeting March 28-30, 2020, in Chicago. This includes five late-breaking clinical trial (LBCT) sessions and three featured clinical research sessions. There also are two LBCT deep-dive sessions where the experts will break down the hottest trials and attendees can find out what the impact might be on the practice of cardiology and patients.
Feature | ACC | February 05, 2020 | Dave Fornell, Editor

The American College of Cardiology (ACC) released a list of the...

New SIR position statement and quality documents highlight interventional radiology effective use of nonsurgical ablation to treat kidney cancer in selected patients
News | Interventional Radiology | February 04, 2020

February 4, 2020 — For some patients, kidney cancer can be effectively treated without surgery, according to the...

The U.S. Food and Drug Administration (FDA) has approved a the CATALYST trial designed to assess Abbott's Amplatzer Amulet left atrial appendage (LAA) occluder for people with atrial fibrillation (AF or AFib). 
News | Left Atrial Appendage (LAA) Occluders | February 03, 2020

February 3, 2020 — The U.S. Food and Drug Administration (FDA) has approved a the...

The Abbott Tendyne transcatheter mitral valve replacement (TMVR) system, left, became the first TMVR device to gain commercial regulatory clearance in the world. It gains European CE mark in January. Another top story in January was the first use of the Robocath R-One robotic cath lab catheter guidance system in Germany.  Watch a VIDEO of the system in use in one of those cases. 

The Abbott Tendyne transcatheter mitral valve replacement (TMVR) system, left, became the first TMVR device to gain commercial regulatory clearance in the world. It gains European CE mark in January. Another top story in January was the first use of the Robocath R-One robotic cath lab catheter guidance system in Germany.  Watch a VIDEO of the system in use in one of those cases. 

News | February 03, 2020 | Dave Fornell, Editor

February 3, 2020 — Here is the list of the most popular content on the Diagnostic and Interventional Cardiology (...

Raj Makkar, M.D., led a multicenter national study comparing outcomes for minimally invasive heart valve replacement to open-heart surgery. Photo by Cedars-Sinai. TAVR performs as well as surgery for aortic valve replacement.

Raj Makkar, M.D., led a multicenter national study comparing outcomes for minimally invasive TAVR heart valve replacement to open-heart surgery. The study showed the two methods have similar outcomes. Photo by Cedars-Sinai.

News | Heart Valve Technology | January 31, 2020

January 31, 2020 — A new study from the ...

Nuance Communications Inc. introduced Nuance Cardiovascular CAPD, a new computer-assisted physician documentation (CAPD) solution designed to help cardiologists improve the quality of complex documentation and the accuracy of reimbursement for cardiac catheterization procedures. The Nuance Cardiovascular CAPD solution is available through a partnership with ZHealth for this solution, which is based on patented algorithms built with ZHealth’s interventional documentation and coding expertise.
News | Cath Lab | January 31, 2020

January 29, 2020 – Nuance Communications Inc. introduced Nuance Cardiovascular CAPD, a new computer-assisted...

Abbott Tendyne TMVR, TMVI system received European CE mark clearance in January 2020. The Abbott Tendyne transcatheter mitral valve replacement (TMVR) system uses an anchor attached to the apex of the heart with a whether line attached to the valve. This helps to keep the valve anchored in the mitral annulus and prevent embolization. This anchor system was used because, unlike the aortic valve, the mitral valve has a very thin landing zone to secure the valve. Prevents LVOT obstruction.

The Abbott Tendyne transcatheter mitral valve replacement (TMVR) system uses an anchor attached to the apex of the heart with a whether line attached to the valve. This helps to keep the valve anchored in the mitral annulus and prevent embolization. This anchor system was used because, unlike the aortic valve, the mitral valve has a very thin landing zone to secure the valve. The design also eliminated any hardware hanging or folding into the left ventricle, which could cause left ventricular outflow track (LVOT) obstruction, which can prevent blood flow through the aortic valve and to the rest of the body.

Feature | Heart Valve Technology | January 30, 2020

January 30, 2020 — The Abbott Tendyne Transcatheter Mitral Valve Implantation (TMVI) system received European CE...

Overlay Init